newsfilter
← Latest News
GlobeNewswire·

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

  • Nkarta, Inc. announced three scientific presentations at ACR Convergence 2026 in Orlando from November 6-11, 2026.
  • Two oral presentations will highlight the safety of NKX019 across autoimmune indications & its clinical activity in idiopathic inflammatory myopathy.
  • One poster presentation will cover clinical activity of NKX019 in systemic sclerosis.
  • The oral presentation on safety outcomes follows fludarabine/cyclophosphamide lymphodepletion & NKX019 therapy in B-cell-mediated autoimmune diseases.
  • Guillermo J. Valenzuela, MD, FACR will present both oral abstracts on November 8 & November 11.
  • Dinesh Khanna, MBBS, MSc will present the poster abstract on systemic sclerosis on November 9.
  • Data is derived from the ongoing Ntrust Phase 1/2 basket studies (NCT06557265 & NCT06733935) evaluating NKX019 in multiple autoimmune conditions.
  • NKX019 is an allogeneic, off-the-shelf CAR-NK cell therapy engineered with a CD19-targeted receptor & membrane-bound IL-15.
  • The Ntrust trials assess safety, pharmacokinetics, pharmacodynamics, & potential for durable remission via elimination of pathogenic B cells.
  • Patients receive a three-dose cycle of NKX019 following lymphodepletion, with additional cycles possible to restore or deepen response.
  • Presentation materials will be available on Nkarta's website after the event.